Loading stock data…
VRTX
$499.65+8.31 (+1.69%)
Market ClosedLast close Jun 29
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vertex Pharmaceuticals Incorporated in the Healthcare sector is trading at $499.65 with a market capitalization of $114.3B. Wall Street consensus targets $548.69 (29 analysts), implying a +9.8% move over the next 12 months. The stock is currently near its 52-week high of $507.92, remaining 13.0% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +9.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.99B↓ | $3.19B↑ | $3.08B↑ | $2.96B↑ | $2.77B |
| Gross Profit | $2.59B↓ | $2.72B↑ | $2.66B↑ | $2.56B↑ | $2.41B |
| Operating Income | $1.14B↑ | $1.13B↓ | $1.24B↑ | $1.15B↑ | $1.03B |
| Net Income | $1.03B↓ | $1.19B↑ | $1.08B↑ | $1.03B↑ | $646.30M |
Peer Comparison
JNJUNHPFE
Fundamentals
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$114.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.41%
Volume
Today's trading volume
1.98M
Recent News
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $491.34, denoting a +2.32% move from the preceding trading day.
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.
The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.
Vertex Pharmaceuticals (VRTX) Stock After Strong Multi‑Year Run Is The Price Still Reasonable
If you are wondering whether Vertex Pharmaceuticals is priced fairly after its recent run, a good starting point is understanding what the current share price implies about future expectations. The stock last closed at US$466.79, with returns of 3.0% over the past week, 7.4% over the past month, 3.2% year to date, 3.7% over one year, 34.5% over three years and 137.2% over five years. This performance raises questions about how much of the story is already reflected in the price. Recent...
Positive Pediatric CASGEVY Data Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals recently reported Phase 3 data showing that its CRISPR-based therapy CASGEVY delivered strong clinical benefits and a consistent safety profile in children ages 5–11 with severe sickle cell disease and transfusion-dependent beta thalassemia, with all evaluable patients achieving the main trial goals. This pediatric dataset, presented at the European Hematology Association Congress and published in the New England Journal of Medicine, supports Vertex’s regulatory push...